A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

被引:78
|
作者
Pillans, PI
Rigby, RJ
Kubler, P
Willis, C
Salm, P
Tett, SE
Taylor, PJ
机构
[1] Princess Alexandra Hosp, Dept Clin Pharmacol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[3] Princess Alexandra Hosp, Renal Transplantat Unit, Woolloongabba, Qld 4102, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
mycophenolic acid; cyclosporin; acute rejection; renal transplantation;
D O I
10.1016/S0009-9120(00)00196-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Although monitoring of cyclosporin (CsA) is standard clinical practice postrenal transplantation. mycophenolic acid (MPA) concentrations are not routinely measured. There is evidence that a relationship exists between MPA area under the concentration-time curve (AUC) and rejection. In this study, a retrospective analysis was undertaken of 27 adult renal transplant recipients. Methods: Patients received CsA and MPA therapy and had a four-point MPA AUC investigation. The relationship between MPA AUC performed in the first week after transplantation, as well as median trough cyclosporin concentrations, and clinical outcomes in the first month posttransplant were evaluated. Results: A total of 12 patients experienced biopsy proven rejection (44.4%) and 4 patients had gastrointestinal adverse events (14.8%). A statistically significant relationship was observed between the incidence of biopsy proven rejection and both MPA AUC (p = 0.02) and median trough CsA concentration (p = 0.008). No relationship between trough MPA concentration and rejection was observed (p = 0.21). Only 3 of 11 (27%) patients with an MPA AUC > 30 mg.h/L and a median trough CsA > 175 mug/L experienced acute rejection, compared with a 56% incidence of rejection for the remaining 16 patients. Patients who experienced adverse gastrointestinal events had significantly lower MPA AUC (p = 0.04), but median trough CsA concentrations were not significantly different (p = 0.24). Further, 3 of these 4 patients had rejection episodes. Conclusions: in addition to standard CsA monitoring, we propose further investigation of the use of a 4-point sampling strategy to predict MPA AUC in the first week posttransplant, which may facilitate optimization of mycophenolate mofetil dose at a rime when patients are most vulnerable to acute rejection. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [11] Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
    Toenshoff, B
    Weber, LT
    Armstrong, VW
    Zimmerhackl, LB
    Oellerich, M
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 208 - 208
  • [12] The nighttime mycophenolic acid area under the curve influences the occurrence of acute rejection in the early stage in renal transplant recipients.
    Satoh, S
    Tada, H
    Tsuchiya, N
    Murakami, M
    Li, ZH
    Hayase, Y
    Suzuki, T
    Habuchi, T
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 229 - 229
  • [13] Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
    Zi-cheng Yu
    Pei-jun Zhou
    Xiang-hui Wang
    Bressolle Françoise
    Da Xu
    Wei-xia Zhang
    Bing Chen
    Acta Pharmacologica Sinica, 2017, 38 : 1566 - 1579
  • [14] Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
    Yu, Zi-cheng
    Zhou, Pei-jun
    Wang, Xiang-hui
    Francoise, Bressolle
    Xu, Da
    Zhang, Wei-xia
    Chen, Bing
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (11) : 1566 - 1579
  • [15] Population analysis and covariates influencing the pharmacokinetics of mycophenolic acid in renal transplant recipients
    Le Meur, YPA
    Szelag, JC
    Toupance, O
    Hoizey, G
    Marquet, P
    Rousseau, A
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 242 - 242
  • [16] Mycophenolic acid population pharmacokinetics in Tunisian renal transplant recipients
    Gaies, E.
    El Jebari, H.
    Jebabli, N.
    Salouage, I.
    Trabelsi, S.
    Charfi, R.
    Lakhal, M.
    Klouz, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 70 - 70
  • [17] Corticosteroid Withdrawal in Renal Transplant Recipients: An Analysis of the Mycophenolic Acid Observational Renal Transplant (MORE) Registry.
    Ueda, K.
    Wiland, A.
    Mccague, K.
    Peddi, V. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 442 - 442
  • [18] Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients
    Okamoto, M
    Wakabayashi, Y
    Higuchi, A
    Kadotani, Y
    Ogino, S
    Ushigome, H
    Akioka, K
    Kaihara, S
    Yoshimura, N
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 859 - 860
  • [19] Plasma level monitoring of mycophenolic acid in renal transplant recipients
    Sarangi, S. C.
    Reeta, K. H.
    Agarwal, S. K.
    Guleria, S.
    Gupta, Y. K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 52 - 52
  • [20] Chronic renal failure in liver transplant recipients treated with cyclosporin A: A retrospective analysis.
    Fisher, NC
    Nightingale, PG
    Gunson, B
    Lipkin, G
    Neuberger, JM
    HEPATOLOGY, 1997, 26 (04) : 435 - 435